Monoclonal antibodies (mAbs) have been known since the 1970s. However, their therapeutic potential in the medical field has recently emerged, with the advancement of manufacturing techniques. Initially exploited mainly in the oncology field, mAbs have become increasingly relevant in Infectious Diseases. Numerous mAbs have been developed against SARS-CoV 2 and have proven their effectiveness, especially in the management of the mild-to-moderate disease. In this review, we describe the monoclonal antibodies currently authorized for the treatment of the coronavirus disease 19 (COVID-19) and offer an insight into the clinical trials that led to their approval. We discuss the mechanisms of action and methods of administration as well as the prophylactic and therapeutic labelled indications (both in outpatient and hospital settings). Furthermore, we address the critical issues regarding mAbs, focusing on their effectiveness against the variants of concern (VoC) and their role now that a large part of the population has been vaccinated. The purpose is to offer the clinician an up-to-date overview of a therapeutic tool that could prove decisive in treating patients at high risk of progression to severe disease.
【저자키워드】 SARS-CoV-2, therapy, monoclonal antibodies, variants, Prophylaxis, 【초록키워드】 COVID-19, Treatment, coronavirus disease, clinical trial, Infectious diseases, antibody, hospital, monoclonal antibody, variants of concern, progression, Prophylactic, management, therapeutic, Patient, Effectiveness, Critical, mechanism, mAbs, mAb, administration, severe disease, high risk, oncology, clinician, indication, therapeutic potential, mild-to-moderate disease, approval, offer, against SARS-CoV, increasingly, Numerous, Initially, 【제목키워드】 scenario, Future, current,